Global Pharmaceutical Glass Packaging Market Research Report – Forecast Till 2026

Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY 1.1 EXECUTIVE SUMMARY 1.1.1 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY PRODUCT 1.1.2 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY MATERIAL TYPE 1.1.3 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY APPLICATION 1.1.4 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY REGION 2 MARKET INTRODUCTION 2.1 DEFINITION 2.2 SCOPE OF THE STUDY 2.3 MARKET STRUCTURE 3 RESEARCH METHODOLOGY 3.1 RESEARCH PROCESS 3.2 PRIMARY RESEARCH 3.3 SECONDARY RESEARCH 3.4 MARKET SIZE ESTIMATION 3.5 FORECAST MODEL 3.6 LIST OF ASSUMPTIONS 4 MARKET DYNAMICS 4.1 INTRODUCTION 4.2 DRIVERS 4.2.1 EXTENDING THE SHELF LIFE OF PRODUCTS 4.2.2 TECHNOLOGICAL DEVELOPMENTS IN PHARMACEUTICAL GLASS PACKAGING 4.2.3 INCREASING DEMAND FROM THE PHARMACEUTICAL INDUSTRY 4.2.4 DRIVERS IMPACT ANALYSIS 4.3 RESTRAINT 4.3.1 GROWING DEMAND FOR PLASTIC PACKAGING 4.3.2 RESTRAINT IMPACT ANALYSIS 4.4 OPPORTUNITY 4.4.1 INCREASING DEMAND IN EMERGING ECONOMIES 4.5 REGULATORY FRAMEWORK 4.5.1 ASPECTS OF PACKAGING 4.5.1.1 GENERAL CONSIDERATIONS 4.5.1.2 COMPLIANCE 4.5.2 PACKAGING MATERIALS AND CLOSURES 4.5.3 QUALITY ASSURANCE ASPECTS OF PACKAGING 4.5.3.1 GENERAL CONSIDERATIONS 4.5.3.2 QUALITY CONTROL 4.5.3.2.1 SAMPLING 4.5.3.2.2 TESTING PROGRAMME 4.5.3.3 INSPECTION AND AUDIT 4.5.3.3.1 RULES 4.5.3.3.2 AUDITS OF SUPPLIERS 4.5.4 PROTECTION OF THE ENVIRONMENT 4.5.4.1 PACKAGING WASTE 4.5.4.2 WASTE POLICIES 4.6 PROFIT MARGIN ANALYSIS 4.7 RELATION BETWEEN CAPACITY UTILIZATION RATE & PRODUCT PRICES 4.7.1 LOW UTILIZATION 4.7.2 FULL UTILIZATION 4.7.3 OVER-UTILIZATION 4.8 CAPAPCITY UTILISATION ANALYSIS 4.8.1 AVERAGE CAPACITY UTILISATION RANGE OF PROMINENT PLAYERS, 2014-2019 4.8.2 ESTIMATED PLANNED AND FORECASTED CAPACITY EXPANSION BY PROMINENT PLAYERS 4.9 COVID-19 IMPACT ANALYSIS 4.9.1 ECONOMIC IMPACT 4.9.1.1 IMPACT ON THE OVERALL PACKAGING INDUSTRY 4.9.2 IMPACT ON PRODUCTION 4.9.3 IMPACT ON GLASS PACKAGING MARKET 4.9.3.1 IMPACT ON SUPPLY CHAIN 4.9.3.2 IMPACT ON RAW MATERIAL 4.9.3.3 CASH FLOW CONSTRAINTS 4.9.4 IMPACT ON WORLD TRADE 5 MARKET FACTOR ANALYSIS 5.1 SUPPLY CHAIN ANALYSIS 5.1.1 RAW MATERIAL SUPPLY 5.1.2 MANUFACTURING 5.1.3 DISTRIBUTION CHANNELS 5.1.4 END USERS 5.2 PORTER’S FIVE FORCES MODEL 5.2.1 THREAT OF NEW ENTRANTS 5.2.2 BARGAINING POWER OF SUPPLIERS 5.2.3 THREAT OF SUBSTITUTES 5.2.4 BARGAINING POWER OF BUYERS 5.2.5 INTENSITY OF RIVALRY 6 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY PRODUCT 6.1 OVERVIEW 6.1.1 VIALS 6.1.2 BOTTLES & JARS 6.1.3 CARTRIDGES & SYRINGES 6.1.4 AMPOULES 7 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY MATERIAL TYPE 7.1 OVERVIEW 7.1.1 TYPE I 7.1.2 TYPE II 7.1.3 TYPE III 8 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY APPLICATION 8.1 OVERVIEW 8.1.1 GENERIC DRUGS 8.1.2 BRANDED DRUGS 8.1.3 BIOLOGICAL DRUGS 9 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY REGION 9.1 OVERVIEW 9.2 NORTH AMERICA 9.2.1 US 9.2.2 CANADA 9.2.3 MEXICO 9.3 EUROPE 9.3.1 GERMANY 9.3.2 UK 9.3.3 FRANCE 9.3.4 ITALY 9.3.5 REST OF EUROPE 9.4 ASIA-PACIFIC 9.4.1 CHINA 9.4.2 JAPAN 9.4.3 INDIA 9.4.4 REST OF ASIA-PACIFIC 9.5 LATIN AMERICA 9.5.1 BRAZIL 9.5.2 ARGENTINA 9.5.3 REST OF LATIN AMERICA 9.6 MIDDLE EAST & AFRICA 9.6.1 UAE 9.6.2 SAUDI ARABIA 9.6.3 SOUTH AFRICA 9.6.4 REST OF MIDDLE EAST & AFRICA 10 COMPETITIVE LANDSCAPE 10.1 INTRODUCTION 10.2 COMPETITIVE OVERVIEW 10.3 MARKET SHARE ANALYSIS 10.4 COMPETITIVE BENCHMARKING 10.5 GERRESHEIMER AG: LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 10.6.1 PRODUCT LAUNCHES/SERVICE DEPLOYMENTS 10.6.2 EXPANSIONS 10.6.3 MERGERS & ACQUISITIONS/INVESTMENTS 10.6.4 PARTNERSHIPS/CONTRACTS & AGREEMENTS 11 COMPANY PROFILES 11.1 GERRESHEIMER AG 11.1.1 COMPANY OVERVIEW 11.1.2 FINANCIAL OVERVIEW 11.1.3 PRODUCTS OFFERED 11.1.4 KEY DEVELOPMENTS 11.1.5 SWOT ANALYSIS 11.1.6 KEY STRATEGIES 11.2 NIPRO CORPORATION 11.2.1 COMPANY OVERVIEW 11.2.2 FINANCIAL OVERVIEW 11.2.3 PRODUCTS OFFERED 11.2.4 KEY DEVELOPMENTS 11.2.5 SWOT ANALYSIS 11.2.6 KEY STRATEGIES 11.3 SCHOTT AG 11.3.1 COMPANY OVERVIEW 11.3.2 FINANCIAL OVERVIEW 11.3.3 PRODUCTS OFFERED 11.3.4 KEY DEVELOPMENTS 11.3.5 SWOT ANALYSIS 11.3.6 KEY STRATEGIES 11.4 SGD PHARMA 11.4.1 COMPANY OVERVIEW 11.4.2 FINANCIAL OVERVIEW 11.4.3 PRODUCTS OFFERED 11.4.4 KEY DEVELOPMENTS 11.5 SHANDONG QIDU PHARMACEUTICAL CO., LTD. 11.5.1 COMPANY OVERVIEW 11.5.2 FINANCIAL OVERVIEW 11.5.3 PRODUCTS OFFERED 11.5.4 KEY DEVELOPMENTS 11.6 BORMIOLI PHARMA S.P.A. 11.6.1 COMPANY OVERVIEW 11.6.2 FINANCIAL OVERVIEW 11.6.3 PRODUCTS OFFERED 11.6.4 KEY DEVELOPMENTS 11.7 ARDAGH GROUP S.A. 11.7.1 COMPANY OVERVIEW 11.7.2 FINANCIAL OVERVIEW 11.7.3 PRODUCTS OFFERED 11.7.4 KEY DEVELOPMENTS 11.7.5 SWOT ANALYSIS 11.7.6 KEY STRATEGIES 11.8 WEST PHARMACEUTICAL SERVICES, INC. 11.8.1 COMPANY OVERVIEW 11.8.2 FINANCIAL OVERVIEW 11.8.3 PRODUCTS OFFERED 11.8.4 KEY DEVELOPMENTS 11.8.5 SWOT ANALYSIS 11.8.6 KEY STRATEGIES 11.9 PIRAMAL ENTERPRISES LIMITED 11.9.1 COMPANY OVERVIEW 11.9.2 FINANCIAL OVERVIEW 11.9.3 PRODUCTS OFFERED 11.9.4 KEY DEVELOPMENTS 11.9.5 SWOT ANALYSIS 11.9.6 KEY STRATEGIES 11.10 STOELZLE OBERGLAS GMBH 11.10.1 COMPANY OVERVIEW 11.10.2 FINANCIAL OVERVIEW 11.10.3 PRODUCTS OFFERED 11.10.4 KEY DEVELOPMENTS 11.11 ARAB PHARMACEUTICAL GLASS CO. 11.11.1 COMPANY OVERVIEW 11.11.2 FINANCIAL OVERVIEW 11.11.3 PRODUCTS OFFERED 11.11.4 KEY DEVELOPMENTS 11.12 ŞİŞECAM GROUP 11.12.1 COMPANY OVERVIEW 11.12.2 FINANCIAL OVERVIEW 11.12.3 PRODUCTS OFFERED 11.12.4 KEY DEVELOPMENTS 11.12.5 SWOT ANALYSIS 11.12.6 KEY STRATEGIES 11.13 OWENS-ILLINOIS INC. 11.13.1 COMPANY OVERVIEW 11.13.2 FINANCIAL OVERVIEW 11.13.3 PRODUCTS OFFERED 11.13.4 KEY DEVELOPMENTS 11.13.5 SWOT ANALYSIS 11.13.6 KEY STRATEGIES 11.14 BECTON, DICKINSON AND COMPANY 11.14.1 COMPANY OVERVIEW 11.14.2 FINANCIAL OVERVIEW 11.14.3 PRODUCTS OFFERED 11.14.4 KEY DEVELOPMENTS 11.14.5 SWOT ANALYSIS 11.14.6 KEY STRATEGIES 12 APPENDIX 12.1 REFERENCE